NFONF yields 9.26% · JNJ yields 2.13%● Live data
📍 NFONF pulled ahead of the other in Year 1
Combined, NFONF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NFONF + JNJ for your $10,000?
NFON AG provides cloud-based telecommunication services to business customers in Germany, Austria, Italy, the United Kingdom, Spain, France, and Portugal. It offers Cloudya and centrexx products for customers with the required brokerage service from the cloud in its data centers through the cloud private branch exchange; and telephone conference services. The company also provides various solutions, such as Nconnect voice for IP communications; Nconnect data, which allows Internet access; Ncontactcenter, a cloud contact centre solution, that facilitates customer support for various channels, agents, and locations; Nhospitality, which integrates cloud telephony into property management systems for hotel industry; Neorecording that allows companies to record conversations and retain them in a tamper-proof and encrypted environment; Nmonitoring Queues to monitor and track internal work performance; and Noperatorpanel, which provides a professional voice reception panel for customers to receive incoming calls and forward certain calls to their intended recipients. In addition, its product portfolio includes unified communications and collaboration, such as Meet and Share; integration for Microsoft Teams; and business applications comprising CRM Connect, as well as sells devices, such as telephones, soft clients for PCs and smartphones, and related software. The company has an agreement with Meetecho. NFON AG was founded in 2007 and is headquartered in Munich, Germany.
Full NFONF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.